Two year old hepatitis A vaccine is as good as new

This was a randomized, controlled, double-blind study assessing the reactogenicity and immunogenicity of newly produced vs 2 year old hepatitis A vaccine. Overall 215 non-immune volunteers, 18-39 years old were divided into four groups and administered vaccine at months 0, 1 and 6. Three groups each received a different vaccine lot which had been stored at 4 degrees C for 2 years, and one group received recently produced vaccine as control. The mean local and general adverse reaction rates were 59.1% and 17.4%, respectively, and all vaccinees had seroconverted by month 2. There were no significant differences in geometric mean anti-hepatitis A virus (HAV) antibody titres between the four groups. In conclusion 2 year old HAV vaccine is safe and equally immunogenic as newly produced vaccine.

Hepatitis B in the non-residential mentally handicapped population

This study describes seroprevalence and risk factors for hepatitis B in seven centres caring for non-residential mentally handicapped individuals. Overall, 11% were hepatitis B marker seropositive and 4% had the hepatitis B surface antigen (HBsAg). Male sex and increasing age were associated with seropositive status, and Down's syndrome was associated with the presence of HBsAg. Immediate family members of those with hepatitis B markers were screened and 22% had evidence of hepatitis B markers. Forty-one family members were identified when the mentally handicapped individual was HBsAg positive and of these 13 (32%) were seropositive. This study demonstrates that hepatitis B is a problem for the non-residential mentally handicapped population and confirms the risk of infection to their immediate families.

Acquired immunodeficiency syndrome

A report entitled "Kaposi's Sarcoma and Pneumocytosis Carinii Pneumonia among homosexual men in New York City and California" in the MMWR in July 1981 alerted the world to the appearance of a completely new disease. The opportunistic infections and cancers occurring in these patients had previously only been seen in patients who were immunosuppressed. Homosexual men were the first as a major risk group to be identified. Others quickly followed. The pattern of occurrence clearly indicated an infectious agent as the likely cause, and within two years the virus had been identified in Europe and the USA. In Europe it was named Lymphadenopathy Associated Virus (LAV) by Montagnier its discover, and in the USA, Human T cell Lymphotrophic Virus III (HTLV III). It is now known as Human Immunodeficiency Virus (HIV).